Login
Aura Biosciences, Inc. logo

Aura Biosciences, Inc.

aurabiosciences.com

What Do They Do?

Develops precision therapies for solid tumors, led by bel-sar for early choroidal melanoma, other eye cancers and bladder cancer.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −23% (Loss)
vs −$26.1M in Q3 FY2025
  • Aug 11, 2026 Aura refocuses on ocular oncology and minimizes bladder cancer program resources The realignment includes an approximately 20% workforce reduction.
  • Apr 29, 2026 Natalie Holles replaces Elisabet de los Pinos as CEO

Who Do They Compete With?

Competes with Immunocore, Ideaya Biosciences, Ferring Pharmaceuticals, ImmunityBio, CG Oncology, Inlexo, UroGen Pharma, Protara Therapeutics, Asieris Pharmaceuticals, and Trya Biosciences

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support